e-Therapeutics (ETX)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

11.00p
   
  • Change Today:
    -0.15p
  • 52 Week High: 23.10
  • 52 Week Low: 8.13
  • Currency: UK Pounds
  • Shares Issued: 584.34m
  • Volume: 169,640
  • Market Cap: £64.28m

E-therapeutics finance chief stepping down due to family

By Josh White

Date: Monday 22 Nov 2021

LONDON (ShareCast) - (Sharecast News) - Drug discovery company E-therapeutics announced on Monday that Karl Keegan was stepping down from his non-board role as chief financial officer, to focus on "extremely difficult" family circumstances in Ireland.
The AIM-traded firm said his resignation would take effect from 31 December.

It said it was actively looking for a new chief financial officer, during which time non-executive director Michael Bretherton would act as interim CFO.

Bretherton had been a director of seven other AIM quoted companies during the last 10 years, including DeepMatter Group, Nanoco Group, Ceres Power and Tissue Regenix Group.

He has a degree in economics from Leeds University, and is a member of the Institute of Chartered Accountants in England and Wales.

Bretherton's early career included working as an accountant and manager with PriceWaterhouse for seven years in London and the Middle East.

"We are very saddened that Karl will be leaving e-therapeutics under these circumstances at the end of the year," said chief executive officer Ali Mortazavi.

"We are grateful to Karl for his contribution to e-therapeutics and wish him the very best in the future."

At 1348 GMT, shares in E-therapeutics were up 2.09% at 46.5p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

e-Therapeutics Market Data

Currency UK Pounds
Share Price 11.00p
Change Today -0.15p
% Change -1.35 %
52 Week High 23.10
52 Week Low 8.13
Volume 169,640
Shares Issued 584.34m
Market Cap £64.28m

e-Therapeutics Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
27.91% below the market average27.91% below the market average27.91% below the market average27.91% below the market average27.91% below the market average
48.15% above the sector average48.15% above the sector average48.15% above the sector average48.15% above the sector average48.15% above the sector average
Price Trend
59.31% below the market average59.31% below the market average59.31% below the market average59.31% below the market average59.31% below the market average
15.79% above the sector average15.79% above the sector average15.79% above the sector average15.79% above the sector average15.79% above the sector average
Income Not Available
Growth
15.52% below the market average15.52% below the market average15.52% below the market average15.52% below the market average15.52% below the market average
18.92% below the sector average18.92% below the sector average18.92% below the sector average18.92% below the sector average18.92% below the sector average

e-Therapeutics Dividends

No dividends found

Trades for 28-Mar-2024

Time Volume / Share Price
16:35 21 @ 11.00p
16:35 2 @ 11.00p
16:35 19 @ 11.00p
16:29 9 @ 10.80p
16:29 9 @ 11.00p

e-Therapeutics Key Personnel

Chair Trevor Mervyn Jones
CEO Ali Mortazavi

Top of Page